高级别非子宫内膜样子宫内膜癌手术与辅助治疗碎片化对生存的影响:一项基于人群的队列研究
该基于人群的回顾性队列研究纳入2003至2017年诊断为高级别非子宫内膜样子宫内膜癌且术后接受辅助治疗的患者1795例,其中583例(32.5%)存在碎片化诊疗。碎片化诊疗与未碎片化诊疗两组的总生存无显著差异。作者认为,在妇科肿瘤医生完成手术后,这些患者可在离家较近处接受辅助治疗以减轻经济与旅行负担。
要点
- 碎片化诊疗定义为手术与辅助治疗在不同机构完成,本队列中占32.5%(583/1795)。
- 碎片化诊疗组与未碎片化诊疗组的总生存无显著差异。
- 未碎片化诊疗组更可能由妇科肿瘤医生手术(92.4% vs 58.8%,P<.001)且手术分期率更高(66.6% vs 44.8%,P<.001)。
核心结论
- 手术与辅助治疗的碎片化对高级别非子宫内膜样子宫内膜癌患者的总生存无不良影响。
- 作者认为,在妇科肿瘤医生完成手术治疗后,这些患者可在离家较近处接受辅助治疗以减轻经济与旅行负担。
研究设计与样本
- 基于人群的回顾性队列研究,纳入2003至2017年诊断为高级别非子宫内膜样子宫内膜癌且术后接受辅助治疗的患者1795例。
- 碎片化诊疗定义为手术与辅助治疗在不同机构完成,非碎片化诊疗定义为手术与辅助治疗在同一机构完成。
- 主要结局为总生存。
主要发现
- 1795例患者中583例(32.5%)存在碎片化诊疗。
- 未碎片化诊疗组较碎片化诊疗组更可能由妇科肿瘤医生手术(92.4% vs 58.8%,P<.001),更可能进行手术分期(66.6% vs 44.8%,P<.001),手术旅行距离更短(平均30.8 km vs 93.7 km,P<.001)。
- 未碎片化诊疗组较碎片化诊疗组更少接受化疗(26.3% vs 30%,P<.001)和放化疗(38.4% vs 41.3%,P<.001)。
- 中位生存期为9年。
- 碎片化诊疗组与未碎片化诊疗组的总生存无显著差异;碎片化诊疗组和未碎片化诊疗组分别有92.4%和93.5%的患者至少部分治疗(手术、辅助治疗或两者)在专科妇科肿瘤中心完成。
临床怎么用
- 作者认为,在妇科肿瘤医生完成手术治疗后,这些患者可在离家较近处接受辅助治疗以减轻经济与旅行负担。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fragmented care (FC) occurs when patients receive treatment across several different hospitals. Regionalization of surgery for patients with high-grade endometrial cancer means that patients must travel longer distances to receive care; these patients often require adjuvant treatment after surgery. OBJECTIVE: To determine whether the fragmentation of surgery and adjuvant treatment impacts survival in patients with high-grade nonendometrioid endometrial cancer. METHODS: This population-based retrospective cohort study included patients diagnosed between 2003 and 2017 with high-grade nonendometrioid endometrial cancer who received adjuvant treatment postoperatively. Nonfragmented care was defined as receiving surgery and adjuvant treatment at the same institution. The primary outcome was overall survival. RESULTS: We identified 1795 patients, of whom 583 (32.5%) had FC. Patients with nonfragmented care were more likely to have had surgery by a gynecologic oncologist (92.4 vs 58.8%, P<.001), surgical staging (66.6 vs 44.8%, P<.001), and less travel for surgery (mean 30.8 km vs 93.7 km, P<.001). They were less likely to receive chemotherapy (26.3 vs 30%, P<.001) and chemoradiation (38.4 vs 41.3%, P<.001). Median survival was 9 years. There was no significant difference in overall survival between patients who received FC and nonfragmented care; 92.4% and 93.5% of the patients in the FC and nonfragmented care groups were treated at a specialized gynecologic oncology center for at least part of their treatment (surgery, adjuvant treatment, or both). CONCLUSION: We have previously shown that regionalization of surgery in high-grade endometrial cancer is associated with improved survival. Fragmentation of surgery and adjuvant treatment in this population does not have an adverse effect on survival. After receiving surgical treatment with a gynecologic oncologist, these patients may receive adjuvant treatment closer to home to decrease financial and travel burden.
引用
- Nica A, Sutradhar R, Kupets R, et al. Effect of fragmentation of surgery and adjuvant treatment in high-grade nonendometrioid endometrial cancer: a population-based cohort study. Am J Obstet Gynecol. 2024. PMID: 39551459. doi:10.1016/j.ajog.2024.11.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。